Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

#25-119 Decision on delisting of Diagonal Bio AB from Nordic SME

Diagonal Bio AB ("the Company"), whose shares are listed on Nordic SME, issued a press release with information that the Lund District Court have declared the Company bankrupt on December 11, 2025. NGM decided to trade halt the shares on December 11, 2025. For more information, see Market Notice #25-118. According to paragraph 3.3.2 in Rules for companies whose shares are listed on Nordic SME the exchange may decide to delist the instruments of an issuer if an application for bankruptcy, liquidation of the business, or a decision regarding an equivalent measure has been taken by the

#25-118 Trading halt in Diagonal Bio AB

NGM has decided to halt the trading in the shares of Diagonal Bio AB effective immediately. Trading will be halted until further notice in accordance with Chapter 11, Section 12 of the Securities Market Act. The Financial Supervisory Authority has been notified about the trade halt and has decided that it will remain until further notice in accordance with Chapter 22, Section 1 of the Securities Market Act.Information regarding the affected instruments:Listing name: Diagonal BioExchange symbol: DIABIOISIN-code: SE0015961826CFI-code: ESVUFRFISN-code: DIAGONALBI/SHInstrument-ID:

Diagonal Bio announces change of news plattform

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that, effective Monday, 28 April 2025, the Company will transition its news distribution service from Cision News to Modular Finance (MFN).Starting from Monday 28 of April, those wishing to subscribe to Diagonal Bio’s news updates can register on the Company’s website . Please note that the system does not allow for subscribers to be transferred from Cision to MFN automatically. All current subscribers are kindly requested to re-subscribe on the Company’s website. For additional

Read original

Diagonal Bio announces additional pilot tests of LAMPlify®

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") is pleased to announce that Diagonal Bio has signed an agreement to conduct pilot tests of the LAMPlify® platform at Stall Törnqvist as well as an undisclosed additional facility. Set to begin in April 2025, the pilot tests will run for three and six months, respectively and aim to improve equine health by enabling the early detection of potential viral infections in horses, ultimately enhancing their overall performance and well-being.Stall Törnqvist, run by Maria Törnqvist, was founded in 2016 and currently houses 100 horses. The

Read original

Diagonal Bio publishes Year-End Report for 2024

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") hereby publishes its year-end report for the financial year 2024. Below is a brief summary. The full year-end report is available on Diagonal Bio's website (www.diagonalbio.com) and as an attached file.Summary of the year-end report for 2024   2024-10-01 — 2024-12-31 (October— December 2024) · Net sales amounted to 62 KSEK (23 KSEK), capitalised development contributed with 281 KSEK (405 KSEK), and other operating income amounted to 1 KSEK (7 KSEK). · Operating loss amounted to -2 260 KSEK (-2 530 KSEK). · Operating

Read original

Diagonal Bio granted patent in Japan

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") announces that the Japanese Patent Office has confirmed the grant of a patent (application number: EP3987059B1) to Diagonal Bio for the Company’s key technology (‘A DNA/RNA detection platform’).At this stage, this patent protection has been extended to Europe, Hong Kong, Israel, Canada, Mexico, South Africa, the UK and Japan. The application is in process in additional countries such as the US, China and Australia. “The granted patent in Japan further strengthens our position and protection. We are continuously working to protect

Read original

Nomination Committee change in Diagonal Bio AB (publ.)

Diagonal Bio announces a change the Nomination Committee for the Annual General Meeting (AGM) on May 20, 2025.According to the instructions for the Nomination Committee adopted by the AGM in 2024, the Nomination Committee for the Diagonal Bios AGM 2025 shall consist of four members, representing the three largest shareholders on September 30th together with the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting

Read original

Trading in Diagonal Bio’s shares and warrants of series TO 2 on NGM Nordic SME begins today

Today, 19 March 2025, is the first day of trading in Diagonal Bio AB’s (publ) ("Diagonal Bio" or "the Company") securities on NGM Nordic SME (“NGM”). The shares are traded with ISIN code SE0015961826 under the ticker DIABIO, the warrants of series TO 2 are traded with ISIN code SE0023615968 under the ticker DIABIO TO2. The shareholders do not need to take any action in connection with the change of marketplace.“The decision to change marketplace was based on the evaluation that the move to NGM will result in lower costs and possibilities for us to allocate more capital to marketing and

Read original

#25-27 Warrants issued by Diagonal Bio AB approved for listing at NGM

Nordic Growth Market NGM AB (“NGM“) has, as previously announced, decided to list the shares in Diagonal Bio AB at NGM. The warrants of series TO2 issued by Diagonal Bio AB are also approved for listing, the first day of trading has been set to March 19, 2025.   Information regarding the affected instrument:   Listing name: Diagonal Bio TO2 Exchange symbol: DIABIO TO2 ISIN-code: SE0023615968 CFI-code: RSSXXR FISN-code: DIAGONALBI/OPT RTS 20250618 Instrument-ID: H6QH Tick size table/liquidity band: A Number of issued warrants: 361 889 384 First day of

#25-23 Diagonal Bio AB approved for listing at NGM

Nordic Growth Market NGM AB (“NGM“) has, as previously announced, decided to list the shares in Diagonal Bio AB at NGM. The first day of trading has been set to March 19, 2025.   Information regarding the affected instruments:   Listing name: Diagonal Bio Exchange symbol: DIABIO ISIN-code: SE0015961826 CFI-code: ESVUFR FISN-code: DIAGONALBI/SH Instrument-ID: H5VY Tick size table/liquidity band: 3 Number of issued shares: 1 214 965 327 First day of trading: 2025-03-19 Market-ID: NSME Segment-ID: NSSE   For more information about this Market

Stall Courant and Diagonal Bio agree to a pilot test of LAMPlify®

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") and Stall Courant, owned by Unibet founder Anders Ström and run by trotting trainer Sabine Kagebrant, have signed an agreement regarding a three-month pilot test of the LAMPlify® platform.Stall Courant, founded in 2005 and located in Heby, Sweden, is home to 35 trotting horses and also operates a breeding program. Sabine Kagebrant joined Stall Courant in 2014 and has served as CEO since 2016. Together with the trotting horse Joviality, Kagebrant has secured victories in several major races. "We at Stall Courant are excited to work

Read original

Diagonal Bio has been approved for delisting from Nasdaq First North Growth Market

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that Nasdaq has approved Diagonal Bio's application for delisting from Nasdaq First North Growth Market (“First North”). The last day of trading on First North is 18 March 2025 and the Company will instead be listed on NGM Nordic SME (“NGM”) with a planned first day of trading on 19 March 2025, provided that no new information emerges that affects the listing.The granting of the delisting application is conditioned by Diagonal Bio fulfilling the formal listing requirements of NGM and thus, that the securities in

Read original

Diagonal Bio has received conditional approval for listing on NGM Nordic SME

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has received conditional approval for listing on NGM Nordic SME (“NGM”). The first day of trading is planned for 19 March 2025. This means that Diagonal Bio changes marketplace from Nasdaq First North Growth Market (“First North”).The decision is conditioned by Diagonal Bio fulfilling the formal listing requirements and that no new information emerges that affects the Company's fulfilment of these requirements. Due to the conditional approval, Diagonal Bio has applied for delisting from First North with a desired last day of

Read original

Diagonal Bio applies for change of marketplace to NGM Nordic SME

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that the Company – in order to be able to reallocate costs – has decided to apply for listing on NGM Nordic SME (“NGM”). The decision is based on the evaluation that the move from Nasdaq First North Growth Market to NGM will result in lower costs and thus possibilities for Diagonal Bio to allocate more of the available capital to marketing and sales.Diagonal Bio has been listed on Nasdaq First North Growth Market since July 2021. The objective is to complete the move during March 2025. For additional information

Read original

Diagonal Bio AB’s announces last day of trading in BTU and first day of trading in warrants of series TO 2

Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, with a subscription period ending on 6 February 2025, has now been registered at the Swedish Companies Registration Office together with the directed issue of units which was conducted at the same time. The Company hereby announces that the last day of trading in BTU (paid subscribed unit) is 24 February 2025, and the cut-off date is 26 February 2025. The first day of trading in warrants of series TO 2 is 28 February 2025.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR

Read original

Diagonal Bio AB resolves on a directed issue of units to all external underwriters

The Board of Directors of Diagonal Bio AB ("Diagonal Bio" or the "Company") has today, based on the authorisation granted by the Extraordinary General Meeting on 17 January 2025 resolved on a directed issue of 2,587,768 units to underwriters (the “Compensation Issue”) in the recently conducted oversubscribed rights issue of units which announced on the 23 December 2024 (the “Rights Issue”). The subscription price in the Compensation Issue is set to SEK 0.18 per unit, corresponding to SEK 0.01 per share, which is the same as the subscription price in the Rights Issue. The warrants of series TO

Read original

Diagonal Bio’s CEO Karin Wehlin increases ownership

Diagonal Bio AB’s (”Diagonal Bio” or the ”Company”) CEO, Karin Wehlin, has directly and through Wehlin’s fully owned company WW Advise AB purchased 8,500,000 shares in the Company to a total price of approximately SEK 170,000 (average price SEK 0.02 per share). The acquisition has been made in the market during 11-12 February 2025."I had a top underwriting commitment in the recently conducted rights issue and since we had such a successful outcome with an oversubscription of the issue, I was not allocated any units besides my pro-rata part. Based on this and of course based on my strong

Read original

Diagonal Bio AB’s rights issue of units oversubscribed

The subscription period in Diagonal Bio AB’s ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6.0 million ended on 6 February 2025 (the "Rights Issue"). The Rights Issue was subscribed to a total of approximately 122 percent, including subscription undertakings, meaning that no underwriting commitments have been utilized. In parallel with the Rights Issue, the Company has carried out the directed issue of units which was announced on 23 December 2024 and approved by the Extraordinary General Meeting 17 January 2025, of initially approximately SEK 1.7

Read original

Stall Goop conducts pilot test of LAMPlify®

Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has signed an agreement with Stall Goop regarding a pilot test of LAMPlify®.  The three-month pilot test, starting in February 2025, aims to enhance equine health and performance by enabling early detection of potential virus infections in horses.Stall Goop is located in Kil, Värmland, and is run by Björn Goop. As a world-leading trotting trainer, Björn Goop has more than 8,000 victories and is thus Sweden’s most victorious trotting trainer of all time. Stall Goop currently carries 150 horses.   Diagonal Bio has since 2024

Read original

Diagonal Bio announces positive pilot test results and secures order from StallZet

Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of the successful completion of the pilot test which started in October 2024 and includes the purchase of LAMPlify® along with associated consumables.On 3rd October 2024, Diagonal Bio announced its partnership with StallZet and Daniel Redén, to conduct a three-month pilot test using LAMPlify to detect respiratory viral infections in StallZet's trotters. StallZet is one of Sweden's leading horse

Read original

The subscription period of Diagonal Bio AB’s rights issue of units commences today

Today, 23 January 2025, the subscription period in Diagonal Bio AB’s ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6 million, with preferential rights for the Company’s existing shareholders, commences (the "Rights Issue"). The subscription period runs until 6 February 2025. The Rights Issue was resolved upon by the Board of Directors on 23 December 2024 and approved by the Extraordinary General Meeting on 17 January 2025, together with the resolution on a directed issue of units (the “Directed Issue”, together, the Rights Issue and the Directed Issue

Read original

Diagonal Bio AB publishes investment memorandum prior to upcoming rights issue of units

The subscription period of Diagonal Bio AB’s ("Diagonal Bio" or the "Company") rights issue of units, which was resolved on 23 December 2024 by the Board of Directors together with the resolution on a directed issue of units, commences tomorrow, 23 January 2025. The Company has prepared an investment memorandum, containing information about the Company as well as about the rights issue of units and the terms and conditions for the rights issue. The investment memorandum is available on Diagonal Bio's website (www.diagonalbio.com).Press release 22 January 2025     NOT FOR RELEASE,

Read original

Nomination Committee change in Diagonal Bio (publ.)

Diagonal Bio announces a change the Nomination Committee for the Annual General Meeting (AGM) on May 20, 2025.According to the instructions for the Nomination Committee adopted by the AGM in 2024, the Nomination Committee for the Diagonal Bios AGM 2025 shall consist of four members, representing the three largest shareholders on September 30th together with the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting

Read original

Bulletin from the Extraordinary General Meeting of Diagonal Bio AB on 17 January 2025

Today, January 17, 2025, an Extraordinary General Meeting was held in Diagonal Bio AB. A summary of the adopted resolutions follows below.Resolution on reduction of the share capital for allocation to non-restricted equity The general meeting resolved, in accordance with the board of directors' proposal, to reduce the company's share capital by a maximum of SEK 7,659,877.37 for allocation to non-restricted equity and without cancellation of shares. The effect of the resolution on a reduction of the share capital is that the share capital and restricted equity will be reduced by a maximum

Read original
There are no items matching the current filter
There are no more items matching the current filter
Back to top